US biotech firm bullish on Chinese business

US biotech company Amgen is aiming at rapid development of its business in China by bringing in more bone and inflammation therapies to build on its robust annual growth in the country.

The enormous growth this year came mainly from the launch of a biologic injection to treat cardiovascular disease, and the product was moving much faster than anticipated, Penny Wan, vice-president and general manager of Amgen Japan, Australia and Asia-Pacific, said during an interview with China Daily.

"We estimate we will see triple-digit growth in China this year," Wan said.